WEC
GBT

Winslow Evans & Crocker’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Winslow Evans & Crocker’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,000
Closed -$42K – 1361
2018
Q4 		$42K Hold
1,000
– – 0.01% 495
2018
Q3 		$38K Buy
+1,000
New +$44.3K 0.01% 538

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Winslow Evans & Crocker's GBT Position: Q1 2019 in Review

Winslow Evans & Crocker sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2019, closing a stake of 1,000 shares — an estimated $42K sold.

Winslow Evans & Crocker first reported a position in GBT in Q3 2018 and held it in 2 quarters. The position peaked at $42K in Q4 2018. 201 funds tracked by Wall St. Rank hold GBT as of Q1 2019.

  • Winslow Evans & Crocker reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Winslow Evans & Crocker sold 1,000 Global Blood Therapeutics, Inc. shares in Q1 2019, an estimated $42K.
  • Winslow Evans & Crocker first reported a position in Global Blood Therapeutics, Inc. in Q3 2018 and held it in 2 quarters.
  • Winslow Evans & Crocker's Global Blood Therapeutics, Inc. position peaked at $42K in Q4 2018.
  • 201 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2019.

Based on Winslow Evans & Crocker's 13F filing for Q1 2019, filed 22 Apr 2019.